Roots Analysis has done a detailed
study on
To order this 500+ page report, which features 160+ figures
and 200+ tables, please visit https://www.rootsanalysis.com/reports/view_document/digital-health-market/208.html
Key Market Insights
§
§
§
§
§
§
§
§
§
§
§
§
§
For more information, please visit https://www.rootsanalysis.com/reports/view_document/digital-health-market-focus-on-digital-therapeutic-monitoring-and-diag/208.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1 Chapter Overview
3.2. Digitization in the Healthcare Sector
3.3. Next-Generation Healthcare Solutions
3.4. Key Concepts Associated with Digital
Health Solutions
3.4.1. Cognitive Behavioral Therapy (CBT)
3.4.2. Internet of Things (IoT)
3.4.3. Big Data
3.4.4. Artificial Intelligence (AI)
3.4.5. Gamification
3.5. Overview of Digital Therapeutics
3.5.1. Key Strategic Initiatives
3.5.1.1. Digital Therapeutics Alliance (DTA)
3.5.1.2. Personal Connected Health (PCH) Alliance
3.5.1.3. Programs Initiated by The Centers for Disease
Control and Prevention (CDC)
3.5.1.4. Health Insurance Portability and Accountability
Act (HIPAA)
3.5.1.5. National Health Service (NHS) Guidelines
3.5.1.6. United States Food and Drug Administration
(USFDA) Regulations for Digital Therapeutics
3.5.2. Product Development and Commercialization
Path for Digital Therapeutics
3.5.2.1. Discovery and Preclinical Phase
3.5.2.2. Clinical Trials and Validation
3.5.2.3. Involving Insurance Providers / Payers
3.5.2.4. Distribution and Marketing
4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Digital Therapeutics: Overall Market
Landscape
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Type of Solution
4.2.3. Analysis by Type of Therapy
4.2.4. Analysis by Purpose of Solution
4.2.5. Analysis by Target Disease Indication(s)
4.2.6. Analysis by Therapeutic Area
4.2.7. Analysis by Target Population
4.3. Digital Therapeutics: Additional
Information
4.3.1. Analysis by Prescription Requirement
4.3.2. Analysis by Duration of Course
4.3.3. Analysis by Cost of Solution
4.4. Digital Therapeutics: List of Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Type of Business Model
4.4.4. Analysis by Location of Headquarters
4.5. Leading Developers: Analysis by Number of
Digital Therapeutics Solutions
4.6. Leading Developers: 4D Bubble Analysis
based on Portfolio Strength, Target Indication and Company Size
4.7. Grid Representation: Analysis by Status
of Development, Type of Solution and Therapeutic Area
4.8. Tree Map Representation: Analysis by
Therapeutic Area and Company Size
4.9. World Map Representation: Analysis of
Regional Activity
4.10. Digital Therapeutics: Information on
Additional Companies
5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions / Key Parameters
5.4. Key Therapeutic Areas
5.4.1. Cardiovascular Disorders
5.4.1.1. Product Competitiveness Analysis
5.4.2. Mental Health Problems
5.4.2.1. Product Competitiveness Analysis
5.4.3. Metabolic Disorders
5.4.3.1. Product Competitiveness Analysis
5.4.4. Neurological Disorders
5.4.4.1. Product Competitiveness Analysis
5.4.5. Substance Use Disorders
5.4.5.1. Product Competitiveness Analysis
5.4.6. Other Therapeutic Areas
5.4.6.1. Product Competitiveness Analysis
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Akili Interactive
6.2.1 Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Big Health
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. dreem
6.4.1. Company Overview
6.4.2. Product Portfolio
6.4.3. Recent Developments and Future Outlook
6.5 Kaia Health
6.5.1. Company Overview
6.5.2. Product Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. Mindmaze
6.6.1. Company Overview
6.6.2. Product Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Omada Health
6.7.1. Company Overview
6.7.2. Product Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Pear Therapeutics
6.8.1. Company Overview
6.8.2. Product Portfolio
6.8.3 Recent Developments and Future Outlook
6.9. Vida Health
6.9.1. Company Overview
6.9.2. Product Portfolio
6.9.3. Recent Developments and Future Outlook
6.10. Voluntis
6.10.1. Company Overview
6.10.2. Product Portfolio
6.10.3. Recent Developments and Future Outlook
6.11. WellDoc
6.11.1. Company Overview
6.11.2. Product Portfolio
6.11.3. Recent Developments and Future Outlook
6.12. Wellthy Therapeutics
6.12.1. Company Overview
6.12.2. Product Portfolio
6.12.3. Recent Developments and Future Outlook
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Digital Therapeutics: Clinical Trial
Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Number of Patients Enrolled and
Trial Registration Year
7.3.4. Analysis by Study Design
7.3.5. Analysis by Trial Recruitment Status
7.3.6. Analysis by Sponsor / Collaborator
7.3.7. Leading Industry Players: Analysis by Number
of Registered Trials
7.3.8 Leading Digital Therapeutic Solutions:
Analysis by Number of Registered Trials
7.3.9. Analysis by Trial Focus
7.3.10. Analysis by Therapeutic Area
7.3.11. Geographical Analysis by Number of Clinical
Trials
7.3.12. Geographical Analysis by Trial Recruitment
Status
7.3.13. Geographical Analysis by Enrolled Patient
Population
7.4. Clinical End-Points Analysis
8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Types of Funding
8.3. Digital Therapeutics: Funding and
Investment Analysis
8.3.1. Analysis by Number of Funding Instances
8.3.2. Analysis by Amount Invested
8.3.3. Analysis by Type of Funding
8.3.4. Analysis by Type of Therapy
8.3.5. Analysis by Therapeutic Area
8.3.6. Analysis by Geography
8.3.7. Most Active Players: Analysis by Number of
Funding Instances
8.3.8. Most Active Players: Analysis by Amount of
Funding
8.3.9. Most Active Investors: Analysis by Number of
Instances
8.4 Concluding Remarks
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Digital Therapeutics: Recent Partnerships
and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.2.1. Analysis by Type of Partnership and Year of
Partnership
9.3.2.2. Analysis by Type of Partnership and Company
Size
9.3.3. Analysis by Type of Partner
9.3.3.1. Analysis by Type of Partner and Year of
Partnership
9.3.3.2. Analysis by Type of Partner and Type of
Partnership
9.3.4. Analysis by Type of Therapy
9.3.4.1. Analysis by Type of Therapy and Type of
Partnership
9.3.4.2. Analysis by Type of Therapy and Type of Partner
9.3.5. Analysis by Therapeutic Area
9.3.5.1. Analysis by Therapeutic Area and Year of
Partnership
9.3.5.2 Analysis by Therapeutic Area and Type of
Partner
9.3.6. Most Active Players: Analysis by Number of
Partnerships
9.3.7. Regional Analysis
9.3.8. Intercontinental and Intracontinental
Agreements
10. GO-TO-MARKET STRATEGY
10.1. Chapter Overview
10.2. Marketing Strategies Adopted by Digital
Therapeutic Developers
10.2.1. Participation in Global Events
10.2.2. Marketing on Social Media Platforms
10.2.3. Marketing on Online / Print Media Platforms
10.2.4. Undertaking Various Promotional Activities
through Official Websites
10.2.5. Adoption of Different Business Models and
Pricing Strategies
10.2.5.1. B2C
Business Model
10.2.5.2. B2B
Business Model
10.2.5.2. B2B2C
Business Model
10.2.6. Undertaking Various Promotional Activities
through Product Add-ons
10.3. Concluding Remarks
11. BOWMAN CLOCK PRICING STRATEGY ANALYSIS
11.1. Chapter Overview
11.2. Bowman Strategy Clock
11.2.1. Two Dimensions of Bowman Strategy Clock
11.2.2. Eight Positions on Bowman Strategic Clock
11.3 Roots Analysis Framework
11.3.1. Methodology
11.3.2. Theoretical Framework and Price Evaluation
Hypothesis
11.3.3. Results and Interpretation
11.3.3.1. Product
Price Evaluation Matrix: Based on Status of Development
11.3.3.2. Product
Price Evaluation Matrix: Based on Type of Solution
11.3.3.3. Product
Price Evaluation Matrix: Based on Purpose of Solution
11.3.3.4. Product
Price Evaluation Matrix: Based on Type of Therapy
11.3.3.5. Product
Price Evaluation Matrix: Based on Therapeutic Area
11.3.3.6. Product
Price Evaluation Matrix: Based on Prescription Requirement
11.3.3.7. Product
Price Evaluation Matrix: Based on Course Duration
11.3.3.8. Product
Price Evaluation Matrix: Based on Distribution Channel
11.4. Concluding Remarks
12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Digital Therapeutics Market,
2020-2030
12.4. Global Digital Therapeutics Market:
Distribution by Type of Solution
12.4.1. Digital Therapeutics Market for Standalone
Software Applications, 2020-2030
12.4.2. Digital Therapeutics Market for Combination
Offerings (Software Application + Device + Personal Coach), 2020-2030
12.4.3. Digital Therapeutics Market for Combination
Offerings (Software Application + Device + AI Support), 2020-2030
12.4.4. Digital Therapeutics Market for Combination
Offerings (Software Application + Device), 2020-2030
12.4.5. Digital Therapeutics Market for Combination
Offerings (Software Application + AI
Support), 2020-2030
12.4.6. Digital Therapeutics Market for Combination
Offerings (Software Application + Personal Coach), 2020-2030
12.4.7. Digital Therapeutics Market for Other Types of
Solutions, 2020-2030
12.5. Global Digital Therapeutics Market:
Distribution by Purpose of Solution
12.5.1. Digital Therapeutics Market for Medication
Replacement Solutions, 2020-2030
12.5.2. Digital Therapeutics Market for Medication
Augmentation Solutions, 2020-2030
12.6. Global Digital Therapeutics Market:
Distribution by Type of Therapy
12.6.1 Digital Therapeutics Market for Curative
Therapy, 2020-2030
12.6.2. Digital Therapeutics Market for Preventive
Therapy, 2020-2030
12.7. Global Digital Therapeutics Market:
Distribution by Business Model
12.7.1. Digital Therapeutics Market for B2C Model
(Patients and Caregivers), 2020-2030
12.7.2. Digital Therapeutics Market for B2B Model
(Healthcare Providers, Payers, Employers
and Pharmaceutical Companies), 2020-2030
12.8. Global Digital Therapeutics Market:
Distribution by Therapeutic Area
12.8.1. Digital Therapeutics Market for Cardiovascular
Disorders, 2020-2030
12.8.2. Digital Therapeutics Market for Chronic Pain,
2020-2030
12.8.3. Digital Therapeutics Market for Mental Health
Problems, 2020-2030
12.8.4. Digital Therapeutics Market for Metabolic
Disorders, 2020-2030
12.8.5. Digital Therapeutics Market for Neurological
Disorders, 2020-2030
12.8.6. Digital Therapeutics Market for Respiratory
Disorders, 2020-2030
12.8.7. Digital Therapeutics Market for Sleep
Disorders, 2020-2030
12.8.8. Digital Therapeutics Market for Substance Use
Disorders, 2020-2030
12.8.9. Digital Therapeutics Market for Other
Disorders, 2020-2030
12.9. Global Digital Therapeutics Market:
Distribution by Geography
12.9.1 Digital Therapeutics Market in North America,
2020-2030
12.9.1.1 Digital
Therapeutics Market in the US, 2020-2030
12.9.1.2 Digital
Therapeutics Market in Canada, 2020-2030
12.9.2 Digital Therapeutics Market in Europe,
2020-2030
12.9.2.1. Digital
Therapeutics Market in France, 2020-2030
12.9.2.2. Digital
Therapeutics Market in Germany, 2020-2030
12.9.2.3. Digital Therapeutics
Market in Italy, 2020-2030
12.9.2.4. Digital
Therapeutics Market in Spain, 2020-2030
12.9.2.5. Digital
Therapeutics Market in the UK, 2020-2030
12.9.2.6. Digital
Therapeutics Market in Rest of Europe, 2020-2030
12.9.3. Digital Therapeutics Market in Asia-Pacific,
2020-2030
12.9.3.1. Digital
Therapeutics Market in Australia, 2020-2030
12.9.3.2. Digital
Therapeutics Market in China, 2020-2030
12.9.3.3. Digital
Therapeutics Market in India, 2020-2030
12.9.3.4. Digital
Therapeutics Market in Japan, 2020-2030
12.9.3.5. Digital
Therapeutics Market in South Korea, 2020-2030
12.9.3.6. Digital
Therapeutics Market in Rest of Asia-Pacific, 2020-2030
12.9.4. Digital Therapeutics Market in Rest of the
World, 2020-2030
13. CASE STUDY: IMPACT OF CORONAVIRUS OUTBREAK
13.1. Chapter Overview
13.2. Impact of Coronavirus Pandemic on Digital
Therapeutics
13.2.1. Impact on Future Market Opportunity for
Digital Therapeutic Solutions Market
13.3. Recuperative Strategies for Developer
Businesses
13.3.1. Strategies for Implementation in the Short /
Mid Term
13.3.2. Strategies for Implementation in the Long Term
14. REMOTE DIGITAL MONITORING / DIAGNOSTIC
SOLUTIONS
14.1. Chapter Overview
14.2. An Introduction to Remote Digital
Monitoring / Diagnostic Solutions
14.3. Remote Digital Monitoring / Diagnostic
Solutions: Overall Market Landscape
14.3.1. Analysis by Status of Development
14.3.2. Analysis by Type of Solution
14.3.3. Analysis by Target Disease Indication(s)
14.3.4. Analysis by Therapeutic Area
14.3.5. Grid Representation: Analysis by Status of
Development, Type of Solution, and Therapeutic
Area
14.4. Remote Digital Monitoring / Diagnostic
Solutions: List of Developers
14.4.1. Analysis by Year of Establishment
14.4.2. Analysis by Company Size
14.4.3. Analysis by Location of Headquarters
14.5. Remote Digital Monitoring / Diagnostic
Solutions: Company Profiles
14.5.1. AliveCor
14.5.1.1. Company
Snapshot
14.5.1.2. Product
Portfolio
14.5.1.3. Recent
Developments and Future Outlook
14.5.2. Bioserenity
14.5.2.1. Company
Snapshot
14.5.2.2. Product
Portfolio
14.5.2.3. Recent
Developments and Future Outlook
14.5.3. Cue
14.5.3.1. Company
Snapshot
14.5.2.2. Product
Portfolio
14.5.2.3. Recent
Developments and Future Outlook
14.5.4. Kinsa
14.5.4.1. Company
Snapshot
14.5.4.2. Product
Portfolio
14.5.4.3. Recent
Developments and Future Outlook
14.6. Remote Digital Monitoring / Diagnostic
Solutions: Funding and Investment Analysis
14.6.1. Types of Funding
14.6.2. Remote Digital Monitoring / Diagnostic
Solutions: List of Funding and Investments
14.6.2.1. Analysis by
Number of Funding Instances
14.6.2.2. Analysis by
Amount Invested
14.6.2.3. Analysis by
Type of Funding
14.6.2.4. Most Active
Players: Analysis by Number of Funding Instances
14.6.2.5. Most Active
Players: Analysis by Amount Invested
14.6.2.6. Most Active
Investors: Analysis by Number of Funding Instances
14.7. Concluding Remarks
15. SWOT ANALYSIS
15.1. Chapter Overview
15.2. Comparison of SWOT Factors
15.2.1. Strengths
15.2.2. Weaknesses
15.2.3. Opportunities
15.2.4. Threats
16. DIGITAL SOLUTIONS: RECENT TRENDS AND
FUTURE OPPORTUNITIES
16.1. Chapter Overview
16.2. Prevalent Trends Related to Digital
Therapeutics
16.2.1. Emerging Focus Areas
16.2.2. Key Historical Trends
16.2.3. Geographical Distribution of Activity
16.3. Trends Shaping the Future of Digital
Therapeutics
16.3.1. Digital Solutions Closing the Digital Gap
16.3.2. Increasing Focus on Patient Centric Models
16.3.3. Applicability across a Variety of Disease Indications
16.3.4. Increasing Emphasis on Real-World Evidence in
Research and Development
16.3.5. Advances in IT and Computing Power to Foster
Future Innovation
16.4. Improving the Future Health: Opportunities
Beyond Digital Therapeutics
17. EXECUTIVE INSIGHTS
17.1. Chapter Overview
17.2. Vida Health
17.2.1. Company Snapshot
17.2.2. Interview Transcript: Stephanie Tilenius,
Co-Founder and Chief Executive Officer
17.3. Canary Health
17.3.1. Company Snapshot
17.3.2. Interview Transcript: Adam Kaufman, Chief Executive Officer
17.4. Floreo
17.4.1. Company Snapshot
17.4.2. Interview Transcript: Vijay Ravidran, Chief Executive Officer
17.5. Somatix
17.5.1. Company Snapshot
17.5.2. Interview Transcript: Eran Ofir, Chief Executive Officer
17.6. Tilak Healthcare
17.6.1. Company Snapshot
17.6.2. Interview Transcript: Edouard Gasser, Chief Executive Officer
17.7. Wellthy Therapeutics
17.7.1. Company Snapshot
17.7.2. Interview Transcript: Palakh R Saraogi, Vice
President Marketing, Arani Sarkra, Senior
Manager Consumer Marketing, and Yolande D’Mello, Marketing and Public
Relations
17.8. Voluntis
17.8.1. Company Snapshot
17.8.2. Interview Transcript: Amelie Janson,
Communications Manager
17.9. Anonymous
17.9.1. Interview Transcript: Anonymous, Founder and
Chief Executive Officer
18. APPENDIX 1: TABULATED DATA
19. APPENDIX 2: LIST OF COMPANIES AND
ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415